menu close
deep

d

Devoted to creating solutions that make a difference. We vow to continuously push the boundaries of therapy to create meaningful pathways through novel GI medical treatments.

e

Explorers by nature. We are curiosity-driven pioneers of new therapeutic frontiers and are inspired by developing groundbreaking science for those who need it most.

e

Equity for all is paramount. From patients to shareholders, no matter who you are, where you’re from, or the life you lead, we believe that every stakeholder deserves a chance to thrive.

p

Patient-focused work is the core of what we do. We are driven by a one-tract mind to do whatever it takes to get patients the answers to their most pressing problems so they can live the life they deserve.

our team

9 Meters is led by a strong management team and board of directors with a deep history of bringing novel GI therapeutics to public markets.

John Temperato

President, Chief Executive Officer & Director

Edward J. Sitar

Chief Financial Officer

Patrick H. Griffin, M.D. FACP

Chief Medical Officer

Sireesh Appajosyula, PharmD

SVP, Corporate Development & Operations

Nir Barak, M.D.

SVP, Scientific Affairs

Matthew Bryant, PharmD

VP, Medical Affairs

board members

Mark Sirgo, PharmD

Chairman of the Board of Directors

Dr. Sirgo is Chief Executive Officer of Aruna Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to the Board from preclinical development through global product commercialization. Most recently, Dr. Sirgo served 13 years as President and CEO of BioDelivery Sciences International (Nasdaq:BDSI), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology. Prior to BDSI, Dr. Sirgo held increasing roles at GSK culminating in Vice President of Clinical Development as well as Senior Vice President of Sales and Marketing for Pharmaceutical Product Development (PPD). Dr. Sirgo served on the Board of Salix, Inc (Nasdaq: SLXP) prior to the sale to Valeant in 2015 and is currently on the Boards of BDSI, Biomerica (Nasdaq:BMRA) and Aruna Bio.

John Temperato

Board of Directors

Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience

Lorin Johnson, PhD

Board of Directors

Dr. Johnson is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company, and held senior leadership positions prior to its ~$16 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as director of scientific operations and chief scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of Glycyx MOR, LTD and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, Intact Inc., a GI specialty drug delivery company based in Belmont, CA, Edesa Biotech (Nasdaq: EDSA) a dermatological and GI company based in Ontario, Canada, and Tumour Trace Ltd, a cancer diagnostic company based in Nottingham, UK. In addition to his career in industry, Dr. Johnson has served as an assistant professor of pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the co-inventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco. We believe that Dr. Johnson’s extensive experience in the pharmaceutical and life science industries, both as an executive and investor, qualifies him to serve on our board of directors.

Michael T. Constantino

Board of Directors

Mr. Constantino joined our Board in June of 2020 and is a retired Ernst & Young LLP assurance partner with more than 30 years of experience. Mr. Constantino has worked closely with companies across various development stages, from early start-up to mature Fortune 250 corporations, and assisted management teams and boards of directors with SEC compliance matters, global operations and strategic planning. During his career, he worked with life science companies, CROs, technology, manufacturing and transportation firms. Mike assisted clients with over 20 IPOs, debt offerings, M & A transactions, and private equity offerings, working closely with companies across the continuum from start-up to mature public entities while assisting management teams and boards with SEC compliance matters, Sarbanes-Oxley internal controls, global operations and strategic planning. He is the Chair of the Board for the NC State Foundation, a member of the NC State Investment Fund Board and Chair of the Board of The Green Chair Project. He has served as the Treasurer for the North Carolina Biotechnology Center, Chairman of the NC State Poole College of Management Board of Advisors, the Board of Directors and Treasurer for Rise Against Hunger (formerly, Stop Hunger Now), Board of Directors and Treasurer for the Council for Entrepreneurial Development, and Chairman and Treasurer for Southeastern Bio. Mike holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina CPA.

Michael Rice

Board of Directors

Mr. Rice is president and co-founder of LifeSci Advisors, a life sciences investor relations consultancy, and the co-founder of LifeSci Capital, a research-driven investment bank, positions he has held since March 2010. Mr. Rice is also a founding member of LifeSci Communications, a corporate communications and public relations firm. From June 2019 to December 2020, Mr. Rice also served as Chief Operating Officer and a member of the Board of LifeSci Acquisition Corp. until its merger with Vincerx Pharma, Inc. (f/k/a Vincera Pharma, Inc.). Prior to co-founding LifeSci Advisors and LifeSci Capital, Mr. Rice was the co-head of health care investment banking at Canaccord Adams from April 2007 to November 2008, where he was involved in debt and equity financing. Mr. Rice was also was a Managing Director at ThinkEquity Partners from April 2005 to April 2007, where he was responsible for managing Healthcare Capital Markets. Prior to that, from August 2003 to March 2005, Mr. Rice served as a Managing Director at Bank of America, serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist. Mr. Rice has been a director of Navidea Biopharmaceuticals Inc. (NYSEA: NAVB) since May 2016 and served as a director of RDD Pharma Ltd. from January 2016 until the Company’s merger with RDD Pharma Ltd. in May 2020. Michael received his B.A. from the University of Maryland. Michael holds Series 7, 24, 63, and 79 licenses.

Samantha Ventimiglia

Board of Directors

Ms. Ventimiglia currently serves as senior vice president, U.S. Public Affairs at Vertex Pharmaceuticals, Inc., where she is responsible for developing and overseeing the company’s policy, government affairs and patient advocacy strategy, including building relationships with state and federal government officials, industry organizations, patient groups and other stakeholders. Previously, Samantha held a similar role as a government affairs director at Astellas Pharma US after a tenure as a principal consultant at Jeffrey J. Kimbell & Associates, a federal government affairs firm representing clients in the healthcare community who are seeking legislative and regulatory solutions to problems related to product approval, coverage and reimbursement and marketing practices. Prior to that, Ms. Ventimiglia was a policy director at the Pharmaceutical Research & Manufacturers of America (PhRMA) and the National Governors Association (NGA) where she played a pivotal role in developing the associations’ policy and legislative agenda on Medicare, Medicaid, private sector health care and FDA issues. She also held legislative positions in the offices of U.S. Senator Olympia J. Snowe and U.S. Congressman Elton Gallegly.

committee composition

Board Member Independent Member Audit Committee Compensation Committee Nominating & Governance Committee
Mark Sirgo, PharmD I M M M
Lorin Johnson, PhD. I M C M
Samantha Ventimiglia I M
Michael T. Constantino I C M
Michael Rice I M C
I = Independent Director C = Chairperson M = Member
access 9 meters news and alerts

Fill out the form below to get customized notifications straight to your inbox.